Impact of a multi-strain L. crispatus-based vaginal synbiotic on the vaginal microbiome: a randomized placebo-controlled trial
A clinical trial of a multi-strain vaginal synbiotic (NCT05659745, registered 12/19/2022 at clinicaltrials.gov) led to an optimal vaginal microbiome dominated by L. crispatus (CST I). The synbiotic led to a significant increase in L. crispatus compared to placebo (p < 0.05), and conversion to CST I was significantly higher with the vaginal synbiotic than with placebo (90 vs 11%; p < 0.002). Mechanistically, the synbiotic reduced Gardnerella vaginalis and Candida, clinically important microbes.
Authors
- Susan Kellogg‐Spadt (ORCID: https://orcid.org/0000-0001-8563-2223)
- Sheri L. Simmons (ORCID: https://orcid.org/0000-0001-7046-8862)
- Sara Gottfried (ORCID: https://orcid.org/0000-0002-0606-1184)
- Eleni A. Greenwood (ORCID: https://orcid.org/0000-0003-1653-902X)
- Diane Medved Harper (ORCID: https://orcid.org/0000-0001-7648-883X)
- Dirk Gevers (ORCID: https://orcid.org/0000-0003-1998-0363)
- Miriam Greene
- Jacques Ravel
Institutions
- University of Maryland, Baltimore (US)
- Thomas Jefferson University (US)
- University of California, San Francisco (US)
- Gender Studies (CZ)
- Clover Seed (China) (CN)
- New York University (US)
- Drexel University (US)
Publication Details
- Journal
- npj Biofilms and Microbiomes
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1038/s41522-025-00788-6
- Citations
- 15
- Primary Topic
- Reproductive tract infections research
- Type
- article
- Field-Weighted Citation Impact
- 17.75